internal
Leonard S. Schleifer
President and Chief Executive Officer; Board Co-Chair
Executive
38 yr
14 reports
Regeneron Pharmaceuticals, Inc. ·REGN
Founder-CEO and founding CSO jointly anchor Regeneron’s science-led org
Health Care · Fortune #306 · Hybrid structure · 15K employees · Tarrytown, New York
View as of:
6
CEO span
↓ tighter than peers (avg 9)
1.3
Avg span
tight
3
Max depth
3 levels
16 yr
Avg tenure
stable vs FY2024
100%
Internal hires
↑ above industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$14.3B
Operating income
$3.6B
Net income
$4.5B
Total assets
$40.6B
Shares out
92M
Sourced from Regeneron Pharmaceuticals, Inc. DEF 14A · filed 2026-04-24 ↗ View on SEC
Interactive org chart
Regeneron Pharmaceuticals, Inc. organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
Founder-CEO Leonard Schleifer and founding CSO George Yancopoulos jointly anchor Regeneron’s leadership, an unusual dual-founder structure for a $14B biotech. This page maps the executive org, highlights the science-led design, reviews recent leadership changes, and compares Regeneron with large-cap biotech peers.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Andrew J. Murphy moved into Executive Vice President, Co-Chief Scientific Officer
Promoted effective January 2026 to newly created Co‑CSO role.
Source · See change logScenario views in the chart
- Add Chief AI Officer Introduce a Chief AI Officer to centralize AI strategy across research and operations.
- Create COO Role Insert a COO layer to consolidate operations and commercial execution under a single leader.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
7 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
internal
George D. Yancopoulos
President and Chief Scientific Officer; Board Co-Chair
Research
37 yr
5 reports
internal
Christopher Fenimore
Executive Vice President, Finance and Chief Financial Officer
Finance
1 yr
3 reports
internal
Andrew J. Murphy
Executive Vice President, Co-Chief Scientific Officer
Research
0 yr
2 reports
internal
Joseph J. LaRosa
Executive Vice President, General Counsel and Secretary
Legal
7 yr
0 reports
internal
Marion McCourt
Executive Vice President, Commercial
Commercial
5 yr
0 reports
internal
Daniel P. Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply
Operations
10 yr
0 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 1 named executive officers disclosed. Bar length scales with total compensation.
Leonard S. Schleifer, M.D., Ph.D. $7.3M
- Base salary
- $1.98M
- Stock awards
- $3.68M
- Option awards
- $1.62M
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The skin in the game
Beneficial ownership
Insider stock holdings and the company's ownership requirements for executives and directors. Disclosed in the most recent DEF 14A.
Stock ownership requirements
6×CEO base salary
2×NEO base salary
Stock ownership guidelines disclosed in proxy.
The businesses
How Regeneron Pharmaceuticals, Inc. divides the work
3 divisions report into the group CEO. Tile size scales with estimated headcount.
Research & Development
6K employees
President and Chief Scientific Officer (George D. Yancopoulos)
Core discovery and translational research organization built around Regeneron’s proprietary genetics and antibody platforms.
Commercial
3K employees
Executive Vice President, Commercial (Marion McCourt)
Global commercialization of approved products including Dupixent and EYLEA franchises.
Industrial Operations & Product Supply
4K employees
EVP and GM, Industrial Operations (Daniel P. Van Plew)
Manufacturing, supply chain, and technical operations supporting global biologics production.
The thesis
Why this org is unusual
Regeneron’s most distinctive structural feature is that both the CEO and the Chief Scientific Officer are company founders who also serve as board co-chairs.
This creates an unusually science-centered power structure where research leadership is not subordinate to a business COO layer. The CEO’s span includes six senior executives, with science represented twice via the CSO and a newly created Co‑CSO role in 2026.
The organization is otherwise functionally aligned: finance, legal, commercial, and industrial operations report directly to the CEO rather than through regional or product presidents. The absence of a standalone COO reinforces the centrality of the CEO and founders in operating decisions. Research has deep tenure and internal promotion, reflecting Regeneron’s long-standing culture of internal scientific leadership development.
- Founder CEO and CSO both serve as board co-chairs
- No Chief Operating Officer role
- Exceptionally long scientific leadership tenure
The comparison
How Regeneron Pharmaceuticals, Inc. stacks up
Compared with large-cap biotech peers like Amgen and Gilead, Regeneron stands out for its dual-founder leadership and lack of a COO. Peers typically separate board chair and CEO roles and elevate a single R&D head beneath a business-focused CEO. Regeneron instead maintains founder control across both governance and …
C-suite size
Reporting depth
Regeneron Pharmaceuticals, Inc.
3 levels
5 levels
5 levels
5 levels
4 levels
Avg C-suite tenure
Regeneron Pharmaceuticals, Inc.
16 yr
6 yr
5 yr
4 yr
Has COO / Has CAIO
Regeneron Pharmaceuticals, Inc. — no COO — no CAIO
Current signals
What changed recently
The most consequential change was the creation of a Co‑Chief Scientific Officer role in January 2026, elevating Andrew Murphy alongside founder George Yancopoulos.
- Date not confirmed promotedAndrew J. Murphy Executive Vice President, Co-Chief Scientific Officer
Promoted effective January 2026 to newly created Co‑CSO role.
Source - Date not confirmed promoted
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-04-24
- CEO
- Leonard S. Schleifer
- CEO span
- 6
- C-suite
- 6
- Avg tenure
- 15 yr
Creation of Co‑Chief Scientific Officer role.
Named executive officers (5)
- Leonard S. Schleifer - CEO since 1988
- George D. Yancopoulos - CSO since 1989
- Christopher Fenimore - CFO since 2025
- Daniel P. Van Plew - EVP Operations since 2016
- Andrew J. Murphy - Co‑CSO since 2026
FY2024
DEF 14A filed 2025-04-29
- CEO
- Leonard S. Schleifer
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 16 yr
Founder-led structure without COO.
Named executive officers (5)
- Leonard S. Schleifer - CEO since 1988
- George D. Yancopoulos - CSO since 1989
- Christopher Fenimore - CFO since 2024
- Daniel P. Van Plew - EVP Operations since 2016
- Andrew J. Murphy - EVP Research since 2019
FY2023
DEF 14A filed 2024-04-30
- CEO
- Leonard S. Schleifer
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 17 yr
Stable founder-dominated executive team.
Named executive officers (3)
- Leonard S. Schleifer - CEO since 1988
- George D. Yancopoulos - CSO since 1989
- Daniel P. Van Plew - EVP Operations since 2016
Year-over-year changes
The executive team expanded with the addition of a Co‑CSO, modestly increasing CEO span.
- CEO span: 5 → 6
- C-suite size: 5 → 6
- Avg tenure: 16 → 15 yr
- promoted Andrew J. Murphy - Co‑Chief Scientific Officer (was EVP Research) (DEF 14A filed 2026-04-24)
Frequently Asked Questions
Who is the CEO of Regeneron Pharmaceuticals?
Leonard S. Schleifer, M.D., Ph.D., has served as President and CEO since founding Regeneron in 1988.
What type of organizational structure does Regeneron Pharmaceuticals use?
Regeneron uses a hybrid, science-led functional structure anchored by founder leadership.
How many direct reports does Regeneron Pharmaceuticals's CEO have?
The CEO has six direct reports, spanning science, finance, legal, commercial, and operations.
How has Regeneron Pharmaceuticals's leadership changed recently?
In January 2026, Regeneron created a Co‑Chief Scientific Officer role, promoting Andrew J. Murphy.
Does Regeneron Pharmaceuticals have a COO?
No. Regeneron does not have a Chief Operating Officer; operations report directly to the CEO.
Sources
- 2026 Proxy Statement, Apr 2026
- SEC EDGAR: Regeneron Pharmaceuticals, Inc. DEF 14A Proxy Statement
- SEC EDGAR: Regeneron Pharmaceuticals, Inc. 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Regeneron Pharmaceuticals, Inc. organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/regeneron-pharmaceuticals/MLA 9th
"Regeneron Pharmaceuticals, Inc. Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/regeneron-pharmaceuticals/. Accessed .Chicago 17
Creately. "Regeneron Pharmaceuticals, Inc. Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/regeneron-pharmaceuticals/.Original SEC source View on SEC ↗
Regeneron Pharmaceuticals, Inc.. DEF 14A. Filed 2026-04-24. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htmPermanent URL: https://creately.com/org-chart/fortune-500/regeneron-pharmaceuticals/ · last updated 2026-04-01